technology — US PTAB Patent Cases
1,070 decisions indexed
Page 21 of 36 · 1,070 total
TransCore, LP v.Hand Held Products, Inc.
TransCore and Hand Held Products entered a confidential settlement and jointly moved to terminate IPR2024‑00443 concerning U.S. Patent 8,919,654. The Board has not yet issued an institution decision.
Samsung Electronics Co., Ltd. et al. v.SiOnyx, LLC
Samsung Electronics and SiOnyx settled their dispute, leading the PTAB to terminate the inter partes review of U.S. Patent No. 10,224,359 before institution. The settlement agreements were ordered confidential.
Samsung Electronics Co., Ltd. et al. v.SiOnyx, LLC
Samsung and SiOnyx reached a settlement that terminated the inter partes review of U.S. Patent 10,224,359 before the trial was instituted. The Board ordered the settlement and related license agreement to be kept confidential.
Samsung Electronics Co., Ltd. et al. v.SiOnyx, LLC
Samsung and SiOnyx settled their inter partes review disputes before the PTAB instituted the trial. The Board granted the joint motion to terminate and ordered the settlement documents to be kept confidential.
Samsung Electronics Co., Ltd. et al. v.SiOnyx, LLC
Samsung and patent‑owner SiOnyx settled their IPR dispute over U.S. Patent 9,905,599 before a trial began. The Board granted a joint motion to terminate and ordered the settlement documents to be kept confidential.
Samsung Electronics Co., Ltd. et al. v.SiOnyx, LLC
Court decision.
Samsung Electronics Co., Ltd. et al. v.SiOnyx, LLC
Samsung Electronics filed a petition to challenge SiOnyx's U.S. Patent No. 10,224,359.
Samsung Electronics Co., Ltd. et al. v.SiOnyx, LLC
Court decision.
Precision Cancer Technologies Inc. v.Oncoustics Inc.
Court decision.
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
The PTAB denied Abbott Laboratories' request for Director Review of the institution decisions in three IPRs, including IPR2025-00116 covering Miracor Medical's patent 11,754,077 B1. The institution decisions remain in effect.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
The PTAB denied Merck's request for Director review of institution decisions in multiple PGRs, including Halozyme's patent 12,018,298. The denial leaves the Board's institution findings intact.
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
The PTAB denied Director Review requests for three IPR institution decisions, including IPR2025-00115 concerning patent 11,674,517 owned by Miracor Medical and challenged by Abbott Laboratories. The institution decisions therefore remain in effect.
PHISON ELECTRONICS CORPORATION v.Vervain, LLC
Phison’s post‑grant review petition includes this exhibit of supporting evidence for its challenge to Vervain’s U.S. Patent 8,891,298.
Sinclair Pharma Limited et al. v.HydraFacial LLC
The USPTO denied Sinclair Pharma’s request for Director Review of the institution decision in IPR2025-00145 concerning HydraFacial’s patent 11,865,287. The institution of the IPR remains in place.
Sinclair Pharma Limited et al. v.HydraFacial LLC
Court decision.
Sinclair Pharma Limited et al. v.HydraFacial LLC
HydraFacial has filed a Director Review request in IPR2025‑00145, restricting the petitioner to a brief, evidence‑free response.
Amazon.com, Inc. et al. v.NL Giken Inc.
Amazon and its affiliates settled the IPR against NL Giken, leading the PTAB to terminate the proceeding.
Amazon.com, Inc. et al. v.NL Giken Inc.
Amazon and its affiliates jointly moved to terminate the IPR over U.S. Patent 10,880,592 after reaching a confidential settlement with NL Giken.
Google LLC et al. v.Mullen Industries LLC
The PTAB upheld the Director’s discretionary denial of institution in IPR2025-00227, finding the review inefficient and unnecessary after prior adjudication and a stipulation not to reassert the claims. Google’s petition for rehearing was rejected.
Google LLC et al. v.Mullen Industries LLC
Google and Samsung petition the PTAB to rehear the Director's discretionary denial of institution for IPR2025-00227, arguing the denial exceeds statutory authority and misapplies the "settled expectations" doctrine.
Liberty Mutual Insurance Company et al. v.Intellectual Ventures II
Liberty Mutual and patent‑owner Intellectual Ventures have jointly moved to terminate IPR2025‑00202 after settling their dispute over U.S. Patent 8,332,844.
Liberty Mutual Insurance Company et al. v.Intellectual Ventures I
Liberty Mutual and Intellectual Ventures settled their inter partes review disputes over three patents, leading the PTAB to terminate the proceedings before institution. The settlement agreements were ordered confidential.
Liberty Mutual Insurance Company et al. v.Intellectual Ventures I
Liberty Mutual filed a joint motion to terminate its IPR against Intellectual Ventures I’s patent 7,949,785.
Liberty Mutual Insurance Company et al. v.Intellectual Ventures I
Liberty Mutual and patent‑holder Intellectual Ventures have settled their dispute over U.S. Patent 7,949,785 and jointly moved to terminate the pending IPR. The motion cites 35 U.S.C. § 317(a) and argues the proceeding is at an early stage with no merits decision.
Liberty Mutual Insurance Company et al. v.Intellectual Ventures I
Liberty Mutual and Intellectual Ventures settled their inter partes review disputes before any trial, leading the Board to terminate the three IPRs. The settlement agreements were treated as confidential business information.
Digital Global Systems, Inc. v.DeepSig Inc.
The USPTO denied Digital Global Systems' request for Director Review of the decision that refused to institute its IPR against DeepSig. The denial leaves the original institution denial in place.
YANGTZE MEMORY TECHNOLOGIES COMPANY, LTD. v.Micron Technology, Inc. et al.
Court decision.
Cisco Systems, Inc. v.WSOU Investments LLC d/b/a Brazos Licensing and Development
Cisco’s petition to reinstate an IPR against WSOU’s 8,982,691 patent was opposed by the patent owner, who argued the Director correctly denied institution based on efficiency factors and the limited weight of the Sotera stipulation.
Cisco Systems, Inc. v.WSOU Investments LLC d/b/a Brazos Licensing and Development
Cisco Systems responded to WSOU Investments’ request for Director Review of the PTAB’s institution decision in IPR2025-00188. The petitioner argues the Board properly considered all relevant factors and exercised discretion, so the review should be denied.
Cisco Systems, Inc. v.WSOU Investments LLC d/b/a Brazos Licensing and Development
Cisco has filed a petition for rehearing after the Director vacated the institution of its IPR against patent 8,982,691. The company argues the Director overstepped authority by demanding a waiver of district‑court defenses.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.